Publications by authors named "Aya Sonezaki"
A 55-year-old woman transitioned from hypothyroidism to Graves' disease (GD) and then developed thyroid eye disease (TED) with proptosis and diplopia. After three cycles of daily methylprednisolone pulse therapy, her condition progressed to dysthyroid optic neuropathy with decreased visual acuity in both eyes. Her clinical activity score (CAS) was 7 points.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the impact of seasonal changes on glycemic control in type 2 diabetes patients during the COVID-19 pandemic, focusing on data from Sugi Cardiovascular Hospital in late 2021.
- A total of 86 patients were analyzed, revealing significant seasonal variations in hemoglobin A1c (HbA1c) levels, particularly higher in spring and lower in autumn over the three years studied (2019-2021).
- Interestingly, despite the pandemic's restrictions, the seasonal trends in glycemic control remained consistent, with no patients contracting COVID-19 during the study period.
Background: Treatment with antiviral drugs for non-severe, early time from onset, adult outpatients with Coronavirus Disease 2019 (COVID-19) had not been established in 2021. However, some new variants of SARS-CoV-2 had caused rapid exacerbation and hospitalization among non-elderly outpatients with COVID-19, contributing to widespread crises within healthcare systems.
Methods: From July to October 2021, we urgently assessed a therapeutic program using oral colchicine (1.
Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
Front Endocrinol (Lausanne)
December 2021
Article Synopsis
- A 24-year-old female CCS with diabetes and dyslipidemia was treated with a mix of insulin and medications, but they didn't work until she was given a combination of metreleptin and empagliflozin, which significantly improved her blood sugar and lipid levels.
- This case suggests that combining metreleptin, which helps with insulin resistance, with an SGLT2 inhibitor, which helps reduce blood sugar, may benefit CCSs by potentially restoring some adipose tissue volume and improving metabolic health.